Methods and devices are provided for reducing the concentration of low molecular weight compounds in a biological composition containing cells while substantially maintaining a desired biological activity of the biological composition. The device comprises highly porous adsorbent particles, and the adsorbent particles are immobilized by an inert matrix. The matrix containing the particles is contained in a housing, and the particles range in diameter from about 100 .mu.m to about 1500 .mu.m. The device can be used to adsorb and remove pathogen-inactivating compounds from a biological composition such as a blood product.

Claims

53 · 1 independent · depth 9

53 granted claims

›1.independentA pathogen-inactivating compound adsorption system for reducing the concentration of a low molecular weight pathogen-inactivating compound in an aqueo…+52

›2.↳ 1A system according to claim 1, wherein the matrix comprises a sintered polymeric matrix.d2+49

›5.↳ 2multiple · 2, 3A system according to claim 2 or 3, wherein the porous adsorbent particles have a surface area greater than about 750 m.sup.2 /g, and the porous adsor…d3+2

›8.↳ 2A system according to claim 2, wherein the matrix contains said porous adsorbent particles.d3+12

›9.↳ 8A system according to claim 8, wherein the porous adsorbent particles comprise a synthetic polymeric adsorbent having a porous network structure and h…d4+7

›10.↳ 8A system according to claim 8, wherein the porous adsorbent particles comprise activated carbon.d4+3

›21.↳ 2A system according to claim 2 wherein the pathogen inactivating compound comprises a nucleic acid-binding compound.d3+32

›22.↳ 21A system according to claim 21, wherein the nucleic acid-binding compound comprises a psoralen derivative.d4

›23.↳ 21A system according to claim 21, wherein the nucleic acid-binding compound comprises an acridine derivative.d4

›24.↳ 21A system according to claim 21, wherein the nucleic acid-binding compound comprises a dye.d4

›25.↳ 21A system according to claim 21, wherein the nucleic acid-binding compound has an electrophilic group or a group capable of forming an electrophilic gr…d4+1

›27.↳ 21A system according to claim 21, wherein the porous adsorbent particles additionally have an affinity for a degradation product of said nucleic acid-bi…d4

›28.↳ 21A method for reducing the concentration of a low molecular weight compound in a biological composition containing cellular elements, wherein said low …d4+19

›29.↳ 28A method according to claim 28, wherein the nucleic acid-binding compound adsorbed onto the porous adsorbent particles of the system comprises an acri…d5+1

›30.↳ 28A method according to claim 28, wherein the nucleic acid-binding compound adsorbed onto the porous adsorbent particles of the system comprises a dye.d5+1

›31.↳ 28A method according to claim 28, wherein the biological composition contacts the porous adsorbent particles and the matrix at a temperature of about 22…d5+13

›32.↳ 31A method according to claim 31, wherein the biological composition comprises platelets.d6+1

›33.↳ 31A method according to claim 31, wherein the biological composition contacts the porous adsorbent particles and the matrix at a temperature of about 22…d6+9

›34.↳ 33A method according to claim 33, wherein the biological composition is treated with the system at a temperature of about 22.degree. C. for between abou…d7+5

›35.↳ 33A method according to claim 33, wherein the biological composition is treated with the system at a temperature of about 22.degree. C. for between abou…d7+1

›44.↳ 33A method according to claim 33, wherein the biological composition comprises a blood product.d7

›42.↳ 31A method according to claim 31, wherein the biological composition comprises a blood product.d6

›39.↳ 28A method according to claim 28, wherein the biological composition comprises a blood product.d5

›48.↳ 21A method for reducing the concentration of a low molecular weight compound in a biological composition containing cellular elements, wherein said low …d4+5

›49.↳ 48A method according to claim 48, wherein no more than about ten percent of an amount of said psoralen nucleic acid-binding compound originally added to…d5+1

›50.↳ 48A method according to claim 48, wherein said psoralen nucleic acid-binding compound is selected from the group consisting of 4'-(4-amino-2-oxa)butyl-4…d5+1

›51.↳ 48A method according to claim 48, wherein the biological composition comprises a blood product.d5

›3.↳ 1A system according to claim 1, wherein the matrix comprises a fibrous matrix.d2+1

Classifications

7 codes

USPC · US Patent Classification

435/2435/283.1530/412530/415435/238530/413435/180

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency

3.4 y

1,259 days filing → grant

Office actions

on the grant's record

Examiner

David M. Naff

art unit —

Law firm

Law firm · Log in to unlock

Citations: 154 back · 0 forward

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.